11/22
02:11 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
11/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/12
01:30 pm
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:15 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/4
08:30 am
sabs
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
Medium
Report
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
11/4
08:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences
9/20
01:09 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
9/19
12:31 pm
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
9/19
07:31 am
sabs
SAB BIO Highlights Data in Multiple Presentations at EASD [Yahoo! Finance]
Low
Report
SAB BIO Highlights Data in Multiple Presentations at EASD [Yahoo! Finance]
9/19
07:24 am
sabs
SAB BIO Highlights Data in Multiple Presentations at EASD
High
Report
SAB BIO Highlights Data in Multiple Presentations at EASD
9/18
06:44 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.